BC
BCTXW
BriaCell Therapeutics Corp.
No data for this timeframe.
Vol
Market Cap$20.1M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$3.5K
Inst. Activity0 buys / 1 sells
Recent Activity
Inst.
UBS Group AG — NEAR_EXIT
314 shares ($24.00)
Inst.
UBS Group AG — TRIM
2,689 shares ($274.00)
Jun 2, 2026
other
BriaCell Therapeutics Announces Closing of Offering
<p align="justify">PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE)
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.5K | — |
| HRT FINANCIAL LP | $1.00 | — |
3 institutional holders with $3.5K total value (88,180 shares) as of 2025-Q4. Top holders: ROYAL, SUSQUEHANNA, HRT.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 225 | $0.00 | 0.0% | — |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 67,111 | $3.5K | 100.0% | — |
| 3 | HRT FINANCIAL LP | 20,844 | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEAR_EXIT | 2,689 | 314 | -88.3% | $24.00 | 2025-Q2 |
| UBS Group AG | TRIM | 6,413 | 2,689 | -58.1% | $274.00 | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 29,058 | 6,413 | -77.9% | $1.9K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
BriaCell Therapeutics Announces Closing of Offering
<p align="justify">PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTX
May 31, 2026
other
BriaCell Therapeutics Announces Pricing of Offering
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL,
May 31, 2026
Clinical Trial
Combination Study of SV-BR-1-GM With Retifanlimab
Phase Phase 2 — COMPLETED
May 31, 2026
clinical_trial_readout
Results Pending: SV-BR-1-GM (Phase 2) — Completed 68d ago
Trial: Combination Study of SV-BR-1-GM With Retifanlimab
Sponsor: BriaCell Therapeutics Corporation
Phase: Phase 2 | Completed: 2026-03-24
Conditions:
May 26, 2026
fda
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 22, 2026
fda
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 15, 2026
other
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 14, 2026
other
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 13, 2026
contract
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 12, 2026
other
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 6, 2026
fda
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
Apr 27, 2026
routine
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL
Apr 21, 2026
fda
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL
Apr 20, 2026
fda
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL
Mar 31, 2026
m_and_a
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW
Mar 18, 2026
fda
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL